21 – 30 of 50
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals
(
- Contribution to journal › Article
- 2021
-
Mark
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
(
- Contribution to journal › Article
-
Mark
Biomarker testing in MCI patients—deciding who to test
(
- Contribution to journal › Article
-
Mark
Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups
(
- Contribution to journal › Article
-
Mark
Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging
(
- Contribution to journal › Article
-
Mark
The bvFTD phenocopy syndrome : a case study supported by repeated MRI, [18F]FDG-PET and pathological assessment
(
- Contribution to journal › Article
-
Mark
Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups
(
- Contribution to journal › Article
-
Mark
In vivo tau pathology is associated with synaptic loss and altered synaptic function
(
- Contribution to journal › Article
- 2020
-
Mark
Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
(
- Contribution to journal › Article
-
Mark
A clinical-radiological framework of the right temporal variant of frontotemporal dementia
(
- Contribution to journal › Article